INCR INC Research Holdings Inc

Syneos Health Partners with Equicare, Optimizing Data Capture and Integration to Accelerate Clinical Trial Research

Syneos Health Partners with Equicare, Optimizing Data Capture and Integration to Accelerate Clinical Trial Research

MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Equicare to use proXimity™, an innovative cloud-based software platform that accelerates the transfer of clinical trial subject data from multiple electronic health records (EHR) to the sponsor’s electronic data capture systems (EDC).

Through the partnership, Syneos Health will use the proXimity platform to automate sponsor data transfers from EHRs to EDCs for clinical trials, helping to accelerate the performance of new therapies for patients. This collaboration support’s the Company’s commitment to listening and learning from sites and adapting to meet their most critical needs.

“At Syneos Health, we are committed to our customers, always. By partnering with Equicare to use proXimity, we are further addressing challenges sites and sponsors face regarding data capture, timelines and quality control,” said Michael Henning, President, Clinical Delivery, Syneos Health. “We’re confident this collaboration will help enhance the clinical trial experience for sites and sponsors by accelerating data entry and management to improve its accuracy and to help speed new therapies to patients.”

Typically, clinical trial subject data is transcribed manually by site coordinators or other staff from the EHR to the EDC, which is time-intensive and error-prone. proXimity automates this process and transfers the selected data from one system to another without the need for manual transcription, dramatically reducing the time needed to transfer data while helping to eliminate transcription errors.

While therapeutically agnostic, the proXimity software was first selected by NEXT Oncology – part of the Syneos Health Catalyst Site Program for phase I studies – as the exclusive tool to automate the transfer of clinical trial data from their EHR to EDC systems to speed the performance of new therapies in clinical trials. The platform now serves as a key tool for clinical trial data management, as well as assists sponsors in gaining access to their data to accelerate cancer research.

In a recently conducted proof of concept exercise where NEXT Oncology utilized proXimity to transfer data from the EHR to the Syneos Health managed EDC database, the data transfer was five times faster than manual entry and the data was transferred with 0% data entry errors, compared to a 3.5% error rate for manual data entry.

“We are using proXimity today for many of our studies and we are realizing the benefits as we are delivering the data to our sponsors more quickly with less errors,” said Dr. Anthony Tolcher, MD, Medical Oncologist and co-founder of NEXT Oncology. “In 2023, NEXT Oncology will utilize proXimity on all studies that utilize Medidata Rave as the EDC. We know this is the future to bring new therapies to cancer patients faster, and we are glad to have Syneos Health’s support with this strategy.”

About Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.  

We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics.  Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. 

Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.  

To learn more about how we are Shortening the distance from lab to life®, visit or .  

Syneos Health Investor Relations Contact: Syneos Health Press/Media Contact:
Ronnie SpeightGary Gatyas
Senior Vice President, Investor RelationsExecutive Director, External Communications

About Equicare Health

Equicare Health is the industry's leading provider of comprehensive care coordination solutions for oncology. EQUICARE CS™ (ECS) is a multi-facility web-based software tool that facilitates patient engagement including patient reported outcomes, patient navigation, survivorship care and a several other clinical tools. proXimity is a tool set designed to automate data transfer between EMRs and EDCs in support of sponsored clinical trials. For more information, visit please visit .

Equicare Health Media Contact:

Marnie Sanders

VP, proXimity

Equicare Health Inc.

+1.303.506.9050



EN
08/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INC Research Holdings Inc

 PRESS RELEASE

Syneos Health Closes Transaction with Private Investment Firms

Syneos Health Closes Transaction with Private Investment Firms Transaction Will Drive Ongoing Transformation and Accelerate Delivery of Tech-Enabled, Fit-for-Purpose Solutions to Biopharma Customers MORRISVILLE, N.C., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced the completion of its acquisition by a consortium of private investment firm affiliates composed of Elliott Investment Management L.P., Patient Square Capital and Veritas Capital. As a result of the...

 PRESS RELEASE

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

Syneos Health Names Terttu Haring President, Clinical Sites & Patients Industry Veteran to Play Critical Role in Leading Global Clinical Operations, Cultivating Site Relationships, Empowering Patients and Shaping Innovative Clinical Trial Solutions MORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients. With nearly 30 years of experience, Dr. Haring will lead the global clinical operations organizat...

 PRESS RELEASE

Syneos Health and Oracle to Expand Relationship to Accelerate Patient ...

Syneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health Equity MORRISVILLE, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic collaboration that will expand its relationship with Oracle. Using the Oracle Cerner Learning Health Network (LHN) and elements of Oracle’s suite of study startup solutions, the companies seek to help reduce the time it takes to recruit patients for clinical studies and increase the diversity of patient pop...

 PRESS RELEASE

Syneos Health, Inc. and Star Parent, Inc. Announce Proposed $1.70 Bill...

Syneos Health, Inc. and Star Parent, Inc. Announce Proposed $1.70 Billion Offering of Senior Secured Notes MORRISVILLE, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Star Parent, Inc. (the “Issuer” or the “Company”) and Syneos Health, Inc. (“Syneos Health”), announced today that, subject to market conditions and other factors, the Issuer intends to offer $1,700,000,000 aggregate principal amount of Senior Secured Notes due 2030 (the “Notes”). The Issuer intends to use the proceeds from the offering together with other financing sources to fund the previously announced acquisition of Syneos Hea...

 PRESS RELEASE

Syneos Health Stockholders Approve Agreement with Private Investment C...

Syneos Health Stockholders Approve Agreement with Private Investment Consortium MORRISVILLE, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that the Company’s stockholders approved an agreement to take the Company private through an acquisition by a consortium of private investment firm affiliates comprised of Elliott Investment Management L.P., Patient Square Capital, and Veritas Capital at a special meeting of stockholders held earlier toda...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch